[Transglycosylation of benzo[h]quinazolines].

This was the first study to apply cyclodextrin glucanotransferases (CGTase, EC 2.4.1.19) produced by mesophilic, thermophilic, alkaliphilic, and halophilic bacilli as well as pullulanase, beta-amylase, beta-galactosidase, and beta-fructofuranosidase for transglycosylation of benzo[h]quinazolines. The combination of CGTase produced by Bacillus stearothermophilus ST-88 and gamma-cyclodextrin (CD) used as a donor of glucosyl residues was the most efficient. The derivatives obtained are water-soluble. The synthesized products have been purified by various chromatographic methods and their fine structures have been determined.

[Production of fructooligosaccharide syrup from sucrose in combination with palatinose and trehalose].

The fructofuranosidases (EC 3.2.1.26) of Aspergillus niger St-0018 and A. foetidus St-0194 were used to produce fructooligosaccharides (FOS) under periodic and continuous conditions. The incorporation of cells into calcium alginate gel gave the most efficient immobilized biocatalysts. The feasibility of transforming residual sucrose into palatinose and trehalulose using isomaltulose synthase (EC 5.4.99.11) was demonstrated.

[Transglycosylation of L-ascorbic acid].

Cyclodextrin glucanotransferases (CGTase, EC 2.4.1.19) produced by mesophilic, thermophilic, and halophilic bacilli, as well as maltase (EC 3.2.1.20) produced by various strains of Saccharomyces cerevisiae have been applied for transglycosylation of L-ascorbic acid using starch, maltodextrin, gamma-cyclodextrin, and maltose as donors of glucosyl residue. The CGTases produced by thermophilic strains are the most efficient. The degree of transglucosylation is more than 60%.

[Combined enzymatic modification of stevioside and rebaudioside A].

Cyclodextrin glucanotransferases (CGTases, EC 2.4.1.19) produced by mesophilic, thermophilic, alkaliphilic, and halophilic bacilli were used for transglycosylating stevioside and rebaudiosides A with the use of starch as a donor. CGTases produced by B. stearothermophilus B-5076 B. macerans BIO-4m were the most effective biocatalysts. This method can be successfully used for direct transglycosylation of stevia extract without purification of its individual components.

[Transglycosylation of stevioside by cyclodextrin glucanotransferases of various group of microorganisms]. / Transgliukozilirovanie steviozida tsiklodeksringliukanotransferazami razlichnykh grupp mikroorganizmov.

Cyclodextrin glucanotransferases (CGTases, EC 2.4.1.19), produced by mesophilic, thermophilic, alkaliphilic, and halophilic bacilli, were used for the transglycosylation of stevioside to remove bitterness and aftertaste, with cyclodextrins (CDs) being used as donors. It was shown that CGTases produced by extremophiic microorganisms are effective biocatalysts. Optimal temperature and pH of these enzymes were at pH 6.5-7.5 and 45 degrees C, respectively. The optimal stevioside-to-CD ratio and total concentration of dry matter for the synthesis of best-taste product were 1:1 (w/w) and 11.6%, respectively.

[Vasonit retard in the treatment of intermittent claudication in patients with obliterating diseases of the lower extremities]. / Vazonit retard v lechenii bol'nykh s peremezhaiushcheisia khromotoi pri obliteriruiushchikh zabolevaniiakh arterii nizhnikh konechnostei.

This paper deals with an open no incomparable study of the efficacy of vasonit retard in the treatment of intermittent claudication in patients suffering from arterial pathology. The efficacy and tolerance of vasonit retard were investigated for two months at the A.V. Vishnevsky Institute of Surgery, RAMS, and at 20 vascular departments of Russia (Moscow, Sankt-Peterburg, Nizhny Novgorod, Perm, Yaroslavl, Volgograd, Omsk, Irkutsk, Chelyabinsk, Voronezh, Rostov-on-Don, Ekaterinburg). The study accrued 25 patients treated at the A.V. Vishnevsky Institute of Surgery, RAMS, and 348 patients treated on the basis of 20 vascular departments of Russia, The basic criterion for inclusion into the study was the presence in the patient of intermittent claudication, corresponding to extremity ischemia, degree IIA end, IIB, according to the A.V.Pokrovsky classification. The treatment by vasonit retard was conducted outpatiently. The drug was administered in a daily dose of 1200 mg for 2 months. After treatment the ankle/brachial index along the posterior tibial artery and dorsalis pedis artery rose by over 17% in the group treated pt the Institute of Surgery and by over 21.5% in the group which participated in the multicenter study. The minimal pain-free distance increased by 60% and 115% respectively. The maximal pain-free distance rose by 37.7% and 98.4% respectively. A 25% abatement of the pain intensity (according to the pain score) was recorded in the group seen at the Institute of Surgery and a 36.1% pain abatement in the group included into the multicenter study. No complications leading to drug discontinuation were marked. Thus, talking into account the clinical evidence and the data supplied by instrumental diagnostic techniques, it is necessary to admit that vasonit retard is an effective drug for the treatment of patients suffering from intermittent claudication.

[Changes in the activity of thrombocytic factors of coagulation in hypercoagulation induced by the administration of adrenaline]. / Izmenenie aktivnosti trombotsitarnykh faktorov svertyvaniia pri giperkoaguliatsii vyzvannoi vvedeniem adrenalina

In adrenaline hypercoagulation and also on addition of adrenaline to platelets in vitro there occurred a marked increase in the activity of the 3rd and the 4th platelet factors; the activity of the 1st and the 2nd platelet factors displayed no significant change under the effect of adrenaline. Hypercoagulation state was accompanied by an accelerated formation of the clot; the process of retraction ends more rapidly.